EMPEROR-Reduced phase III trial positive for Jardiance as a treatment for heart failure.- Boehringer Ingelheim + Eli Lilly

Positive top-line results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, were announced by Boehringer Ingelheim and Eli Lilly and Company). EMPEROR-Reduced met its primary endpoint, demonstrating superiority with Jardiance (empagliflozin) 10 mg compared to placebo in reducing the risk for the composite of cardiovascular death or hospitalization due to heart failure, when added to standard of care. Overall the safety profile was similar to the known safety profile of Jardiance. Full results from the EMPEROR-Reduced trial will be presented in a hot line session at the European Society of Cardiology (ESC) Congress 2020 on August 29, and regulatory submissions are planned in 2020. A second trial, EMPEROR-Preserved, is exploring the effect of Jardiance on cardiovascular death or hospitalization in adults with heart failure with preserved ejection fraction – an area with no approved treatment options. EMPEROR-Preserved results are expected in 2021.